Ripatec

Ripatec

Repasudil

0.4%

Dosage Form & Strength

Apply 1 drop once a day, twice a day.

Dosage in Special Population

Pregnant women It should be given to pregnant women or women who may be pregnant only when the therapeutic benefit outweighs the risk. Lactating women Consider breastfeeding continuation or discontinuation in consideration of therapeutic benefit and breastfeeding benefit. Children No clinical trials have been conducted targeting efficacy and safety in children.

Indications

Ripatec is indicated for the treatment of Glaucoma & ocular hypertension

Adverse Effects

Conjunctival hyperemia, conjunctivitis (including allergicconjunctivitis), blepharitis (including allergic blepharitis),, eye irritation were common adverse effects observed in clinical trials with Repasudil

Mechanism of Action

Ripasudil’s mechanism of action affects intraocular pressure, or IOP, by directly acting on the trabecular meshwork, thereby increasing conventional outflow through the Schlemm’s canal. More simply, it is an “out-flow” drug that reduces IOP by stimulating the movement of aqueous humour from the ciliary body away from the eye. It is a selective rho-associated coiled-coil-containing protein kinase 1 (ROCK1) inhibitor, where ROCK1 is “an important downstream effector of Rho guanosine trisphosphates (GTP), proteins that are significant in the contractile control of smooth muscle tissue.

Pharmacokinetics

Tmax（0.083 hr） Cmax（0.622 ng/mL） t1/2（0.455 hr） When the drug (50 μL) was monocularly instilled in male rabbits, the highest concentrations (68135.4 ng/g and 4126.39 ng / mL) were reached in 0.25 hours in the cornea and atrial water, and then quickly disappeared. In the lens, the highest concentration (154.37 ng/g) was reached in 0.5 hours, and then it disappeared gradually

Drug Use in Pregnancy

pregnant women It should be given to pregnant women or women who may be pregnant only when the therapeutic benefit outweighs the risk. Lactating women Consider breastfeeding continuation or discontinuation in consideration of therapeutic benefit and breastfeeding benefit. It has been reported in animal experiments (rat: oral administration) that it is transferred to milk.

Drug Use in Pediatric Population

Children No clinical trials have been conducted targeting efficacy and safety in children.